Gold prices fall as geopolitical tensions ease; U.S. CPI looms
On June 5, 2025, Peter Stegagno, the Chief Operating Officer of SANUWAVE Health, Inc. (OTC:SNWV), executed several stock transactions involving the company’s common stock. The company, currently valued at $255 million, has seen its shares surge over 335% in the past year according to InvestingPro data. The most significant transaction was the sale of 1,862 shares at a weighted-average price of $27.71, totaling $51,596. The shares were sold in multiple transactions at prices ranging from $27.59 to $27.82. The stock currently trades at $30.16, suggesting continued momentum after these transactions. InvestingPro analysis indicates the stock is trading above its Fair Value, with 8 additional key insights available to subscribers.
Additionally, Stegagno exercised options to acquire 1,862 shares of common stock at prices ranging from $15 to $22.50. The total value of these acquisitions was $31,897. Following these transactions, Stegagno’s direct ownership of SANUWAVE Health common stock stands at 2,032 shares. Despite recent strong price performance, with a 15% gain in the past week, the company maintains a GOOD financial health score according to InvestingPro metrics.
In other recent news, Sanuwave Health, Inc. has made significant changes to its leadership team and board of directors. The company announced the appointment of Dustin Libby as Executive Vice President of Commercial Operations. Libby brings two decades of experience in the medical device sector, having previously held key roles at firms like Abiomed (NASDAQ:ABMD), where he significantly expanded their surgical business. Additionally, Sanuwave appointed Greg Bazar to its board of directors, following the resignation of long-time board member A. Michael Stolarski. Bazar, an expert in engineering and cybersecurity, will also serve on the Compensation Committee, receiving stock options as part of his compensation. Sanuwave’s CEO, Morgan Frank, expressed confidence in both Libby and Bazar, highlighting their potential contributions to the company’s growth in the wound care market. These leadership changes align with Sanuwave’s broader strategy to enhance its market position and improve patient outcomes through innovative technologies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.